Ciclopirox oral - BioTheryX
Alternative Names: BTX-10504; Ciclopirox olamineLatest Information Update: 29 Apr 2016
Price :
$50 *
At a glance
- Originator BioTheryX
- Developer BioTheryX; The Leukemia & Lymphoma Society; University Health Network
- Class Antifungals; Proteins; Pyridones; Small molecules
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
Most Recent Events
- 29 Apr 2016 No recent reports on development identified - Phase-I for Acute myeloid leukaemia, Multiple myeloma and Myelodysplastic syndromes (Second-line therapy or greater) in Canada (PO)
- 02 Dec 2010 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)